Linerixibat
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment[1][2][3].
Product Specifications
CAS Number
1345982-69-5
Product Name Alternative
GSK2330672
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335, H401, H411
Target
Apical Sodium-Dependent Bile Acid Transporter
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/GSK2330672.html
Purity
99.88
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)CC(NCC1=C(OC)C=C(C2=C1)[C@@H](C3=CC=CC=C3)N[C@](CC)(CCCC)CS2(=O)=O)CC(O)=O
Molecular Formula
C28H38N2O7S
Molecular Weight
546.68
Precautions
H302, H315, H319, H335, H401, H411
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
St8sia1 Mouse shRNA Lentiviral Particle (Locus ID 20449)
Anti-human Complement C5 (Crovalimab Biosimilar)
Anti-human Complement C5 (Crovalimab Biosimilar)